Proteasome inhibition for the treatment of glioblastoma

References

• Ostrom QT, Cioffi G, Gittleman H, et al. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2012–2016. Neuro Oncol. 2019 Nov 1;21(Supplement_5):v1–v100. PubMed PMID: 31675094; PubMed Central PMCID: PMCPMC6823730.
   PubMedGoogle Scholar
• Louis DN, Perry A, Reifenberger G, et al. The 2016 world health organization classification of tumors of the central nervous system: a summary. Acta Neuropathol. 2016 June;131(6):803–820. PubMed PMID: 27157931.
   PubMed Web of Science ®Google Scholar
• Parsons DW, Jones S, Zhang X, et al. An integrated genomic analysis of human glioblastoma multiforme. Science. 2008 Sept 26;321(5897):1807–1812. PubMed PMID: 18772396; PubMed Central PMCID: PMCPMC2820389.
   PubMed Web of Science ®Google Scholar
• Gramatzki D, Dehler S, Rushing EJ, et al. Glioblastoma in the Canton of Zurich, Switzerland revisited: 2005 to 2009. Cancer. 2016 July 15;122(14):2206–2215. PubMed PMID: WOS:000379894000013.
   PubMed Web of Science ®Google Scholar
• Wen PY, Weller M, Lee EQ, et al. Glioblastoma in adults: a society for neuro-oncology (SNO) and European society of neuro-oncology (EANO) consensus review on current management and future directions. Neuro Oncol. 2020 Apr 24. DOI:10.1093/neuonc/noaa106. PubMed PMID: 32328653.
   Web of Science ®Google Scholar
• Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005 Mar 10;352(10):987–996. PubMed PMID: 15758009.
   PubMed Web of Science ®Google Scholar
• Weller M, Le Rhun E, Preusser M, et al. How we treat glioblastoma. ESMO Open. 2019;4(Suppl 2):e000520. PubMed PMID: 31297242; PubMed Central PMCID: PMCPMC6586206.
   PubMedGoogle Scholar
• Le Rhun E, Preusser M, Roth P, et al. Molecular targeted therapy of glioblastoma. Cancer Treat Rev. 2019 Nov;80:101896. PubMed PMID: 31541850.
   PubMed Web of Science ®Google Scholar
• Stupp R, Taillibert S, Kanner A, et al. Effect of Tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: a randomized clinical trial. JAMA. 2017 Dec 19;318(23):2306–2316. PubMed PMID: 29260225; PubMed Central PMCID: PMCPMC5820703.
   PubMed Web of Science ®Google Scholar
• Taphoorn MJB, Dirven L, Kanner AA, et al. Influence of treatment with tumor-treating fields on health-related quality of life of patients with newly diagnosed glioblastoma a secondary analysis of a randomized clinical trial. JAMA Oncol. 2018 Apr;4(4):495–504. PubMed PMID: WOS:000429834400011.
   PubMed Web of Science ®Google Scholar
• Chinot OL, Wick W, Mason W, et al. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med. 2014 Feb 20;370(8):709–722. PubMed PMID: 24552318.
   PubMed Web of Science ®Google Scholar
• Gilbert MR, Dignam JJ, Armstrong TS, et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med. 2014 Feb 20;370(8):699–708. PubMed PMID: 24552317.
   PubMed Web of Science ®Google Scholar
• Wick W, Gorlia T, Bendszus M, et al. Lomustine and bevacizumab in progressive glioblastoma. N Engl J Med. 2017 Nov 16;377(20):1954–1963. PubMed PMID: 29141164.
   PubMed Web of Science ®Google Scholar
• Wirsching HG, Tabatabai G, Roelcke U, et al. Bevacizumab plus nypofractionated raciotnerapy versus radiotherapy alone in elderly patients with glioblastoma: tie randomized, open-label, phase II ARTE trial. Ann Oncol. 2018 June;29(6):1423–1430. PubMed PMID: WOS:000438508100018.
   PubMed Web of Science ®Google Scholar
• Stupp R, Hegi ME, Gorlia T, et al. Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2014 Sept;15(10):1100–1108. PubMed PMID: 25163906.
   PubMed Web of Science ®Google Scholar
• Weller M, Butowski N, Tran DD, et al. Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial. Lancet Oncol. 2017 Oct;18(10):1373–1385. PubMed PMID: 28844499.
   PubMed Web of Science ®Google Scholar
• Reardon DA, Brandes AA, Omuro A, et al. Effect of nivolumab vs bevacizumab in patients with recurrent glioblastoma. The CheckMate 143 phase 3 randomized clinical trial. JAMA Oncol. 2020 May 21;6:1003. Online ahead of print.
   PubMed Web of Science ®Google Scholar
• Teicher BA, Tomaszewski JE. Proteasome inhibitors. Biochem Pharmacol. 2015 July 1;96(1):1–9. PubMed PMID: 25935605.
   PubMed Web of Science ®Google Scholar
• McGrath JP, Jentsch S, Varshavsky A. UBA 1: an essential yeast gene encoding ubiquitin-activating enzyme. Embo J. 1991 Jan;10(1):227–236. PubMed PMID: 1989885; PubMed Central PMCID: PMCPMC452634.
   PubMed Web of Science ®Google Scholar
• Groll M, Heinemeyer W, Jager S, et al. The catalytic sites of 20S proteasomes and their role in subunit maturation: a mutational and crystallographic study. Proc Natl Acad Sci U S A. 1999 Sept 28;96(20):10976–10983. PubMed PMID: 10500111; PubMed Central PMCID: PMCPMC34229.
   PubMed Web of Science ®Google Scholar
• Heinemeyer W, Fischer M, Krimmer T, et al. The active sites of the eukaryotic 20 S proteasome and their involvement in subunit precursor processing. J Biol Chem. 1997 Oct 3;272(40):25200–25209. PubMed PMID: 9312134.
   PubMed Web of Science ®Google Scholar
• Rock KL, Goldberg AL. Degradation of cell proteins and the generation of MHC class I-presented peptides. Annu Rev Immunol. 1999;17:739–779. PubMed PMID: 10358773.
   PubMed Web of Science ®Google Scholar
• Gandolfi S, Laubach JP, Hideshima T, et al. The proteasome and proteasome inhibitors in multiple myeloma. Cancer Metastasis Rev. 2017 Dec;36(4):561–584. PubMed PMID: 29196868.
   PubMed Web of Science ®Google Scholar
• Kisselev AF, Goldberg AL. Proteasome inhibitors: from research tools to drug candidates. Chem Biol. 2001 Aug;8(8):739–758. PubMed PMID: 11514224.
   PubMed Web of Science ®Google Scholar
• Broemer M, Meier P. Ubiquitin-mediated regulation of apoptosis. Trends Cell Biol. 2009 Mar;19(3):130–140. PubMed PMID: 19217783.
   PubMed Web of Science ®Google Scholar
• Thibaudeau TA, Smith DM. A practical review of proteasome pharmacology. Pharmacol Rev. 2019 Apr;71(2):170–197. PubMed PMID: 30867233; PubMed Central PMCID: PMCPMC6423620.
   PubMed Web of Science ®Google Scholar
• Chen X, Barton LF, Chi Y, et al. Ubiquitin-independent degradation of cell-cycle inhibitors by the REGgamma proteasome. Mol Cell. 2007 June 22;26(6):843–852. PubMed PMID: 17588519; PubMed Central PMCID: PMCPMC2031223.
   PubMed Web of Science ®Google Scholar
• Imajoh-Ohmi S, Kawaguchi T, Sugiyama S, et al. Lactacystin, a specific inhibitor of the proteasome, induces apoptosis in human monoblast U937 cells. Biochem Biophys Res Commun. 1995 Dec 26;217(3):1070–1077. PubMed PMID: 8554559.
   PubMed Web of Science ®Google Scholar
• Shinohara K, Tomioka M, Nakano H, et al. Apoptosis induction resulting from proteasome inhibition. Biochem J. 1996 July 15;317(Pt 2):385–388. PubMed PMID: 8713062; PubMed Central PMCID: PMCPMC1217499.
   PubMedGoogle Scholar
• Orlowski RZ, Eswara JR, Lafond-Walker A, et al. Tumor growth inhibition induced in a murine model of human Burkitt’s lymphoma by a proteasome inhibitor. Cancer Res. 1998 Oct 1;58(19):4342–4348. PubMed PMID: 9766662.
   PubMed Web of Science ®Google Scholar
• Eskandari SK, Seelen MAJ, Lin G, et al. The immunoproteasome: an old player with a novel and emerging role in alloimmunity. Am J Transplant. 2017 Dec;17(12):3033–3039. PubMed PMID: 28719024.
   PubMed Web of Science ®Google Scholar
• Adams J, Palombella VJ, Sausville EA, et al. Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res. 1999 June 1;59(11):2615–2622. PubMed PMID: 10363983.
   PubMed Web of Science ®Google Scholar
• Orlowski RZ, Stinchcombe TE, Mitchell BS, et al. Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. J Clin Oncol. 2002 Nov 15;20(22):4420–4427. PubMed PMID: 12431963.
   PubMed Web of Science ®Google Scholar
• Richardson PG, Barlogie B, Berenson J, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med. 2003 June 26;348(26):2609–2617. PubMed PMID: 12826635.
   PubMed Web of Science ®Google Scholar
• Richardson PG, Sonneveld P, Schuster MW, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med. 2005 June 16;352(24):2487–2498. PubMed PMID: 15958804.
   PubMed Web of Science ®Google Scholar
• San Miguel JF, Schlag R, Khuageva NK, et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med. 2008 Aug 28;359(9):906–917. PubMed PMID: 18753647.
   PubMed Web of Science ®Google Scholar
• Kane RC, Dagher R, Farrell A, et al. Bortezomib for the treatment of mantle cell lymphoma. Clin Cancer Res. 2007 Sept 15;13(18 Pt 1):5291–5294. PubMed PMID: 17875757.
   PubMed Web of Science ®Google Scholar
• Manasanch EE, Orlowski RZ. Proteasome inhibitors in cancer therapy. Nat Rev Clin Oncol. 2017 July;14(7):417–433. PubMed PMID: 28117417; PubMed Central PMCID: PMCPMC5828026.
   PubMed Web of Science ®Google Scholar
• Richardson PG, Briemberg H, Jagannath S, et al. Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol. 2006 July 1;24(19):3113–3120. PubMed PMID: 16754936.
   PubMed Web of Science ®Google Scholar
• Arastu-Kapur S, Anderl JL, Kraus M, et al. Nonproteasomal targets of the proteasome inhibitors bortezomib and carfilzomib: a link to clinical adverse events. Clin Cancer Res. 2011 May 1;17(9):2734–2743. PubMed PMID: 21364033.
   PubMed Web of Science ®Google Scholar
• Siegel DS, Martin T, Wang M, et al. A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma. Blood. 2012 Oct 4;120(14):2817–2825. PubMed PMID: 22833546; PubMed Central PMCID: PMCPMC4123387.
   PubMed Web of Science ®Google Scholar
• Groen K, van de Donk N, Stege C, et al. Carfilzomib for relapsed and refractory multiple myeloma. Cancer Manag Res. 2019;11:2663–2675. PubMed PMID: 31037034; PubMed Central PMCID: PMCPMC6450182.
   PubMed Web of Science ®Google Scholar
• Yang J, Wang Z, Fang Y, et al. Pharmacokinetics, pharmacodynamics, metabolism, distribution, and excretion of carfilzomib in rats. Drug Metab Dispos. 2011 Oct;39(10):1873–1882. PubMed PMID: 21752943.
   PubMed Web of Science ®Google Scholar
• Efentakis P, Kremastiotis G, Varela A, et al. Molecular mechanisms of carfilzomib-induced cardiotoxicity in mice and the emerging cardioprotective role of metformin. Blood. 2019 Feb 14;133(7):710–723. PubMed PMID: 30482794.
   PubMed Web of Science ®Google Scholar
• Moreau P, Masszi T, Grzasko N, et al. Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2016 Apr 28;374(17):1621–1634. PubMed PMID: 27119237.
   PubMed Web of Science ®Google Scholar
• Tzogani K, Florez B, Markey G, et al. European medicines agency review of ixazomib (Ninlaro) for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. ESMO Open. 2019;4(5):e000570. PubMed PMID: 31555488; PubMed Central PMCID: PMCPMC6735670.
   PubMed Web of Science ®Google Scholar
• Ito S. Proteasome inhibitors for the treatment of multiple myeloma. Cancers (Basel). 2020 Jan 22;12(2):265. PubMed PMID: 31979059; PubMed Central PMCID: PMCPMC7072336.
   Web of Science ®Google Scholar
• Feling RH, Buchanan GO, Mincer TJ, et al. Salinosporamide A: a highly cytotoxic proteasome inhibitor from a novel microbial source, a marine bacterium of the new genus salinospora. Angew Chem Int Ed Engl. 2003 Jan 20;42(3):355–357. PubMed PMID: 12548698.
   PubMed Web of Science ®Google Scholar
• Potts BC, Albitar MX, Anderson KC, et al. Marizomib, a proteasome inhibitor for all seasons: preclinical profile and a framework for clinical trials. Curr Cancer Drug Targets. 2011 Mar;11(3):254–284. PubMed PMID: 21247382; PubMed Central PMCID: PMCPMC3712795.
   PubMed Web of Science ®Google Scholar
• Levin N, Spencer A, Harrison SJ, et al. Marizomib irreversibly inhibits proteasome to overcome compensatory hyperactivation in multiple myeloma and solid tumour patients. Br J Haematol. 2016 Sept;174(5):711–720. PubMed PMID: 27161872; PubMed Central PMCID: PMCPMC5084787.
   PubMed Web of Science ®Google Scholar
• Miller CP, Ban K, Dujka ME, et al. NPI-0052, a novel proteasome inhibitor, induces caspase-8 and ROS-dependent apoptosis alone and in combination with HDAC inhibitors in leukemia cells. Blood. 2007 July 1;110(1):267–277. PubMed PMID: 17356134; PubMed Central PMCID: PMCPMC1896116.
   PubMed Web of Science ®Google Scholar
• Badros A, Singh Z, Dhakal B, et al. Marizomib for central nervous system-multiple myeloma. Br J Haematol. 2017 Apr;177(2):221–225. PubMed PMID: 28387460.
   PubMed Web of Science ®Google Scholar
• Richardson PG, Zimmerman TM, Hofmeister CC, et al. Phase 1 study of marizomib in relapsed or relapsed and refractory multiple myeloma: NPI-0052-101 Part 1. Blood. 2016 June 2;127(22):2693–2700. PubMed PMID: 27009059; PubMed Central PMCID: PMCPMC5413296.
   PubMed Web of Science ®Google Scholar
• Wagenknecht B, Hermisson M, Eitel K, et al. Proteasome inhibitors induce p53/p21-independent apoptosis in human glioma cells. Cell Physiol Biochem. 1999;9(3):117–125. PubMed PMID: 10494025.
   PubMedGoogle Scholar
• Zanotto-Filho A, Braganhol E, Battastini AM, et al. Proteasome inhibitor MG132 induces selective apoptosis in glioblastoma cells through inhibition of PI3K/Akt and NFkappaB pathways, mitochondrial dysfunction, and activation of p38-JNK1/2 signaling. Invest New Drugs. 2012 Dec;30(6):2252–2262. PubMed PMID: 22367315.
   PubMed Web of Science ®Google Scholar
• Kahana S, Finniss S, Cazacu S, et al. Proteasome inhibitors sensitize glioma cells and glioma stem cells to TRAIL-induced apoptosis by PKCepsilon-dependent downregulation of AKT and XIAP expressions. Cell Signal. 2011 Aug;23(8):1348–1357. PubMed PMID: 21440622.
   PubMed Web of Science ®Google Scholar
• Roth P, Kissel M, Herrmann C, et al. SC68896, a novel small molecule proteasome inhibitor, exerts antiglioma activity in vitro and in vivo. Clin Cancer Res. 2009 Nov 1;15(21):6609–6618. PubMed PMID: 19825946.
   PubMed Web of Science ®Google Scholar
• Yin D, Zhou H, Kumagai T, et al. Proteasome inhibitor PS-341 causes cell growth arrest and apoptosis in human glioblastoma multiforme (GBM). Oncogene. 2005 Jan 13;24(3):344–354. PubMed PMID: 15531918.
   PubMed Web of Science ®Google Scholar
• Unterkircher T, Cristofanon S, Vellanki SH, et al. Bortezomib primes glioblastoma, including glioblastoma stem cells, for TRAIL by increasing tBid stability and mitochondrial apoptosis. Clin Cancer Res. 2011 June 15;17(12):4019–4030. PubMed PMID: 21525171.
   PubMed Web of Science ®Google Scholar
• Koschny R, Holland H, Sykora J, et al. Bortezomib sensitizes primary human astrocytoma cells of WHO grades I to IV for tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis. Clin Cancer Res. 2007 June 1;13(11):3403–3412. PubMed PMID: 17545549.
   PubMed Web of Science ®Google Scholar
• Gong X, Schwartz PH, Linskey ME, et al. Neural stem/progenitors and glioma stem-like cells have differential sensitivity to chemotherapy. Neurology. 2011 Mar 29;76(13):1126–1134. PubMed PMID: 21346220; PubMed Central PMCID: PMCPMC3269770.
   PubMed Web of Science ®Google Scholar
• Labussiere M, Pinel S, Delfortrie S, et al. Proteasome inhibition by bortezomib does not translate into efficacy on two malignant glioma xenografts. Oncol Rep. 2008 Nov;20(5):1283–1287. PubMed PMID: 18949434.
   PubMed Web of Science ®Google Scholar
• Rahman MA, Gras Navarro A, Brekke J, et al. Bortezomib administered prior to temozolomide depletes MGMT, chemosensitizes glioblastoma with unmethylated MGMT promoter and prolongs animal survival. Br J Cancer. 2019 Oct;121(7):545–555. PubMed PMID: 31413318; PubMed Central PMCID: PMCPMC6888814.
   PubMed Web of Science ®Google Scholar
• Bota DA, Alexandru D, Keir ST, et al. Proteasome inhibition with bortezomib induces cell death in GBM stem-like cells and temozolomide-resistant glioma cell lines, but stimulates GBM stem-like cells’ VEGF production and angiogenesis. J Neurosurg. 2013 Dec;119(6):1415–1423. PubMed PMID: 24093630; PubMed Central PMCID: PMCPMC4550014.
   PubMed Web of Science ®Google Scholar
• Yoo JY, Jaime-Ramirez AC, Bolyard C, et al. Bortezomib treatment sensitizes oncolytic HSV-1-treated tumors to NK cell immunotherapy. Clin Cancer Res. 2016 Nov 1;22(21):5265–5276. PubMed PMID: 27390350; PubMed Central PMCID: PMCPMC5093037.
   PubMed Web of Science ®Google Scholar
• Areeb Z, Stylli SS, Ware TM, et al. Inhibition of glioblastoma cell proliferation, migration and invasion by the proteasome antagonist carfilzomib. Med Oncol. 2016 May;33(5):53. PubMed PMID: 27098175..
   PubMed Web of Science ®Google Scholar
• Manton CA, Johnson B, Singh M, et al. Induction of cell death by the novel proteasome inhibitor marizomib in glioblastoma in vitro and in vivo. Sci Rep. 2016;6:18953. PubMed PMID: 26804704; PubMed Central PMCID: PMCPMC4726202.
   PubMed Web of Science ®Google Scholar
• Di K, Lloyd GK, Abraham V, et al. Marizomib activity as a single agent in malignant gliomas: ability to cross the blood-brain barrier. Neuro Oncol. 2016 June;18(6):840–848. PubMed PMID: 26681765; PubMed Central PMCID: PMCPMC4864261.
   PubMed Web of Science ®Google Scholar
• Bota DA, Di K, Keator DB, et al. Human functional brain imaging data support preclinical and clinical evidence that marizomib crosses the blood-brain barrier (BBB) to inhibit proteasome activity in the brain. Cancer Res. 2019;79(13 Suppl):Abstractnr 4733.
   Web of Science ®Google Scholar
• Phuphanich S, Supko JG, Carson KA, et al. Phase 1 clinical trial of bortezomib in adults with recurrent malignant glioma. J Neurooncol. 2010 Oct;100(1):95–103. PubMed PMID: 20213332; PubMed Central PMCID: PMCPMC3811025.
   PubMed Web of Science ®Google Scholar
• Kong XT, Nguyen NT, Choi YJ, et al. Phase 2 study of bortezomib combined with temozolomide and regional radiation therapy for upfront treatment of patients with newly diagnosed glioblastoma multiforme: safety and efficacy assessment. Int J Radiat Oncol Biol Phys. 2018 Apr 1;100(5):1195–1203. PubMed PMID: 29722661.
   PubMed Web of Science ®Google Scholar
• Raizer JJ, Chandler JP, Ferrarese R, et al. A phase II trial evaluating the effects and intra-tumoral penetration of bortezomib in patients with recurrent malignant gliomas. J Neurooncol. 2016 Aug;129(1):139–146. PubMed PMID: 27300524.
   PubMed Web of Science ®Google Scholar
• Friday BB, Anderson SK, Buckner J, et al. Phase II trial of vorinostat in combination with bortezomib in recurrent glioblastoma: a north central cancer treatment group study. Neuro Oncol. 2012 Feb;14(2):215–221. PubMed PMID: 22090453; PubMed Central PMCID: PMCPMC3266383.
   PubMed Web of Science ®Google Scholar
• Odia Y, Kreisl TN, Aregawi D, et al. A phase II trial of tamoxifen and bortezomib in patients with recurrent malignant gliomas. J Neurooncol. 2015 Oct;125(1):191–195. PubMed PMID: 26285768.
   PubMed Web of Science ®Google Scholar
• McCracken DJ, Celano EC, Voloschin AD, et al. Phase I trial of dose-escalating metronomic temozolomide plus bevacizumab and bortezomib for patients with recurrent glioblastoma. J Neurooncol. 2016 Oct;130(1):193–201. PubMed PMID: 27502784.
   PubMed Web of Science ®Google Scholar
• Bota D, Desjardins A, Mason W, et al. Full enrollment results from the phase 1/2, multicenter, open-label study of marizomib (MRZ) ± bevacizumab (BEV) in recurrent WHO grade IV malignant glioma (glioblastoma, rGBM). Neuro Oncol. 2017;19(suppl_6):vi16.
   Google Scholar
• Taal W, Oosterkamp HM, Walenkamp AM, et al. Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial. Lancet Oncol. 2014 Aug;15(9):943–953. PubMed PMID: 25035291.
   PubMed Web of Science ®Google Scholar
• Mason WP, Kesari S, Stupp R, et al. Full enrollment results from an extended phase I, multicenter, open label study of marizomib (MRZ) with temozolomide (TMZ) and radiotherapy (RT) in newly diagnosed glioblastoma (GBM). J Clin Oncol. 2019;37(suppl; abstr 2021):2019.
   Google Scholar
• Wallington-Beddoe CT, Sobieraj-Teague M, Kuss BJ, et al. Resistance to proteasome inhibitors and other targeted therapies in myeloma. Br J Haematol. 2018 July;182(1):11–28. PubMed PMID: 29676460.
   PubMed Web of Science ®Google Scholar
• Barrio S, Stuhmer T, Da-Via M, et al. Spectrum and functional validation of PSMB5 mutations in multiple myeloma. Leukemia. 2019 Feb;33(2):447–456. PubMed PMID: 30026573.
   PubMed Web of Science ®Google Scholar
• Oerlemans R, Franke NE, Assaraf YG, et al. Molecular basis of bortezomib resistance: proteasome subunit beta5 (PSMB5) gene mutation and overexpression of PSMB5 protein. Blood. 2008 Sept 15;112(6):2489–2499. PubMed PMID: 18565852.
   PubMed Web of Science ®Google Scholar
• Fuchs D, Berges C, Opelz G, et al. Increased expression and altered subunit composition of proteasomes induced by continuous proteasome inhibition establish apoptosis resistance and hyperproliferation of Burkitt lymphoma cells. J Cell Biochem. 2008 Jan 1;103(1):270–283. PubMed PMID: 17516511.
   PubMed Web of Science ®Google Scholar
• Selimovic D, Porzig BB, El-Khattouti A, et al. Bortezomib/proteasome inhibitor triggers both apoptosis and autophagy-dependent pathways in melanoma cells. Cell Signal. 2013 Jan;25(1):308–318. PubMed PMID: 23079083.
   PubMed Web of Science ®Google Scholar
• Markovina S, Callander NS, O’Connor SL, et al. Bortezomib-resistant nuclear factor-kappaB activity in multiple myeloma cells. Mol Cancer Res. 2008 Aug;6(8):1356–1364. PubMed PMID: 18708367; PubMed Central PMCID: PMCPMC2587345.
   PubMed Web of Science ®Google Scholar
• Kale AJ, Moore BS. Molecular mechanisms of acquired proteasome inhibitor resistance. J Med Chem. 2012 Dec 13;55(23):10317–10327. PubMed PMID: 22978849; PubMed Central PMCID: PMCPMC3521846.
   PubMed Web of Science ®Google Scholar
• Keime-Guibert F, Chinot O, Taillandier L, et al. Radiotherapy for glioblastoma in the elderly. N Engl J Med. 2007 Apr 12;356(15):1527–1535. PubMed PMID: 17429084.
   PubMed Web of Science ®Google Scholar
• Herrlinger U, Tzaridis T, Mack F, et al. Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA-09): a randomised, open-label, phase 3 trial. Lancet. 2019 Feb 16;393(10172):678–688. PubMed PMID: 30782343.
   PubMed Web of Science ®Google Scholar
• Lin GL, Wilson KM, Ceribelli M, et al. Therapeutic strategies for diffuse midline glioma from high-throughput combination drug screening. Sci Transl Med. 2019 Nov 20;11(519). DOI:10.1126/scitranslmed.aaw0064. PubMed PMID: 31748226.
   Web of Science ®Google Scholar